Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Summary

This is a forecasted federal grant opportunity (R33 mechanism) from the National Institutes of Health (NIH/NCI) focused on the advanced development and validation of emerging technologies applicable to basic and clinical cancer research. The R33 mechanism supports the later-stage development phase of exploratory research tools and technologies. Clinical trials are explicitly not allowed under this funding opportunity. The opportunity is identified under RFA-CA-26-002 and is expected to open in September 2025.

What they want

How they evaluate

Risks & flags

• Opportunity is currently in 'forecasted' status — full requirements, eligibility, and evaluation criteria are not yet published
• No dollar values, deadlines, or detailed scope have been disclosed; intelligence is limited